Cella D, et al. - The changes in quality of life (QoL) of patients randomly assigned 1:1 to receive cabozantinib or everolimus for advanced renal cell carcinoma in the phase III METEOR trial were determined. The cabozantinib arm showed improved progression-free survival, overall survival, and objective response rate compared with everolimus. With respect to everolimus, cabozantinib generally maintained the QoL to a similar extent in patients with advanced renal cell carcinoma, and extended time to deterioration (TTD) overall and markedly improved TTD in patients with bone metastases.